Zobrazeno 1 - 10
of 253
pro vyhledávání: '"V, VAVROVA"'
Autor:
Stéphanie Bui, Thierry Bienvenu, Philippe Reix, Gabriel Bellon, Emanuelle Girodon, E. Deneuville, Isabelle Sermet-Gaudelus, Nathalie Stremmler, Albert Iron, Veronika Skalická, Michel Roussey, F. Huet, Delphine Roussel, Gérard Lenoir, M. Lebourgeois, V. Vavrova, Dorota Sands, Milan Macek, Aleksander Edelman, Jacques Sarles, Anne Munck, Isabelle Fajac
Publikováno v:
American Journal of Respiratory and Critical Care Medicine. 182:929-936
The diagnosis of cystic fibrosis (CF) is based on a characteristic clinical picture in association with a sweat chloride (Cl(-)) concentration greater than 60 mmol/L or the identification of two CF-causing mutations. A challenging problem is the sign
Autor:
J. Ticha, V. Vavrova, Jiri Kukacka, Karel Kotaska, Magdalena Kuzelova, M. Halacova, Richard Prusa
Publikováno v:
Journal of Clinical Pharmacy and Therapeutics. 33:409-417
SUMMARY Background and objective: Monitoring of renal function in cystic fibrosis (CF) patients is essential. The dosage regimen of amikacin is regularly modified according to the patient’s glomerular filtration rate (GFR). The aim of the study was
Publikováno v:
Journal of Inherited Metabolic Disease. 31:457-461
Genetic polymorphism of serum transferrin (Tf) was studied in order to differentiate between protein genetic variants and congenital disorders of glycosylation (CDG), further focusing on unusual findings.Screening of Tf hypoglycosylation was carried
Autor:
Anna Sediva, Milan Macek, Jitka Brazova, J. Bartosova, Kristyna Sismova, V. Vavrova, Hynek Lauschman
Publikováno v:
Clinical Immunology. 121:350-357
There is a significant phenotypic variance among cystic fibrosis (CF) patients. Due to the role of TGF-beta1 in fibrotic processes we investigated its role in CF pathogenesis. TGF-beta 1 codons 10 and 25 were genotyped in 118 Czech CF patients and 26
Autor:
Ondrej Cinek, Petr Pohunek, Eshwar Mahenthiralingam, V. Vavrova, P. Drevinek, J. Bartosova, Sarka Vosahlikova
Publikováno v:
Journal of Medical Microbiology. 54:655-659
The morbidity and mortality rates in patients with cystic fibrosis (CF) are significantly affected by infections with Burkholderia cepacia complex. In a Czech CF Centre, the prevalence of the infection reached up to 30 %, with the majority of patient
Publikováno v:
Scopus-Elsevier
UNLABELLED Patients with cystic fibrosis (CF) are underweight and growth retarded. This study tested the link between serum insulin-like growth factor-I (IGF-I) and insulin-like growth factor-binding protein-3 (IGFBP-3) levels and body height, nutrit
Publikováno v:
Allergy & Clinical Immunology International - Journal of the World Allergy Organization. 13:0067-0070
Autor:
V. Vavrova, Veronika Skalická, Klara Dedeckova, Pavel Drevinek, Dana Zemkova, Libor Fila, T. Kucerova, Lucie Kalferstova, Oto Melter, J. Bartosova, Ondrej Cinek
Publikováno v:
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society. 11(5)
Background Once the outbreak with Burkholderia cenocepacia ST32 was identified in the Prague cystic fibrosis (CF) centre, molecular tools were implemented into diagnostic routine in order to complement infection control measures with as accurate as p
Autor:
M. Proesmans, Steven P. Conway, V. Vavrova, K. De Boeck, Lena Hjelte, G. Canny, Burkhard Tümmler, Diana Bilton, S. Dumcius
Publikováno v:
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society. 10
Pulmonary exacerbations represent a key outcome variable in clinical trials of cystic fibrosis (CF). As there is variation in the trigger for use of intravenous antibiotics compared to the use of oral antibiotics or new nebulised therapy for treatmen
Autor:
S. Dumcius, Niels Høiby, V. Vavrova, H. Kollberg, C. Bohmova, Lena Hjelte, Tacjana Pressler, Burkhard Tümmler, Steven P. Conway
Publikováno v:
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society. 10
Chronic pulmonary infection with P. aeruginosa develops in most patients with cystic fibrosis (CF); by adulthood 80% of patients are infected and chronic P. aeruginosa infection is the primary cause of increased morbidity and mortality in CF. Chronic